Warning Letter — HealthPartners Neuroscience Center Research and Innovation
The FDA's Center for Drug Evaluation and Research issued a Warning Letter to HealthPartners Neuroscience Center Research and Innovation following an inspection of their clinical research practices. The specific nature of the violations is not detailed in the provided excerpt but originates from CDER compliance oversight.
This affects clinical investigators, site management organizations, and quality assurance personnel at HealthPartners Neuroscience Center, as well as sponsors conducting drug trials at this facility.
A Warning Letter from CDER indicates that previously identified non-compliance issues may not have been adequately addressed or were of sufficient severity to warrant formal enforcement. This suggests potential risks to data integrity or subject safety within the site's clinical trials, which could lead the FDA to reject data from studies conducted at this location. Regulatory professionals should monitor this for implications on ongoing or future NDAs involving this site.
Clinical research sites should perform immediate internal audits of investigator oversight, documentation protocols, and adherence to investigational plans to ensure compliance with human subject protection and data integrity standards. Regulatory teams should review existing CAPA plans for any outstanding observations from previous inspections.
FDA Warning Letter issued to: HealthPartners Neuroscience Center Research and Innovation. 05/19/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healthpartners-neuroscience-center-research-and-innovation-725333-05192026
Open in openFDA / FDA.gov